Physician profile
Frank Hwang
NPI 1548433600
$2,517.36
in general payments reported to CMS, 2019-2025
24 companies · $677 in 2025
The $677 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $196 · 2021: $84.29 · 2022: $354 · 2023: $592 · 2024: $371 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,626 · Travel and Lodging: $14.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,626.30 |
| Travel and Lodging | $14.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,210.55 | 2019-2025 | Clareon, Hydrus Microstent, Argos |
| Carl Zeiss Meditec USA, INC. | $175.57 | 2024 | Quatera 700, Iolmaster 700 |
| Johnson & Johnson Surgical Vision, INC. | $151.85 | 2022-2025 | Tecnis Simplicity, Tecnis Iol, Veritas Vision System |
| Allergan, INC. | $130.50 | 2019-2021 | |
| Rxsight INC | $128.59 | 2022 | |
| Organogenesis INC. | $107.56 | 2025 | Apligraf |
| Glaukos Corporation | $69.00 | 2022-2024 | Photrexa |
| Bausch & Lomb Americas INC. | $68.45 | 2023-2025 | Envista Mx60 Iol, Scoutpro Osmolarity System, Ic-8 Apthera Iol |
| Dompe US, INC. | $66.86 | 2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $61.18 | 2019-2022 | |
| Harrow Eye, LLC | $55.75 | 2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $44.86 | 2019 | |
| Mallinckrodt Enterprises LLC | $34.86 | 2019 | |
| Oyster Point Pharma, INC. | $27.09 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $26.16 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $26.03 | 2023 | Flarex |
| Aerie Pharmaceuticals, INC. | $23.66 | 2020 | |
| Amgen INC. | $22.69 | 2025 | Tepezza |
| Biotissue Holdings INC. | $20.77 | 2025 | |
| Shire North American Group INC | $18.58 | 2019 | |
| Apellis Pharmaceuticals, INC. | $17.15 | 2022 | |
| Omeros Corporation | $16.66 | 2019 | |
| Mallinckrodt Hospital Products INC. | $11.33 | 2021 | |
| Travere Therapeutics, INC. | $1.66 | 2020-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.